McDonald’s Aims for a Classier Crowd with Lobster Rolls
As sales continue to fall, McDonald’s is desperately trying to reinvent itself, and its latest efforts seem to be aimed at a slightly classier crowd.
New England-area McDonald’s are going to start selling lobster rolls again after a 10-year hiatus, according to a report on Fox CT. No word yet on whether the old name McLobster will be revived.
The new lobster roll is reportedly made from 100 percent North Atlantic lobster, and includes mayonnaise, a bed of lettuce, and a small, toasted roll.
The meal has 290 calories and sells for $7.99.
McDonald’s introduced lobster rolls nationwide for the first time in 1993. Although the launch was a commercial disappointment, the rolls were still available seasonably in New England until 2005. Select McDonald’s restaurants in Canada also offer them for a limited time each year.
There were several reasons for the 1993 McLobster’s failure. Not only were customers wary of a “quality” seafood item served at a fast food chain, but the roll cost $5.99 (about $7.50 in 2015 dollars), a high price relative to the rest of menu.
The new lobster roll will also be expensive and doubts about the quality of its fast food continue to haunt the house that Ronald built. Given those barriers and the company’s track record, it seems unlikely that this particular crustacean-based sandwich is going to be driving a meaningful revival for McDonald’s any time soon.
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
